Perini Guilherme Fleury, Fischer Thais, Gaiolla Rafael Dezen, Rocha Talita Bueno, Bellesso Marcelo, Teixeira Larissa Lane Cardoso, Delamain Marcia Torresan, Scheliga Adriana Alves de Souza, Ribeiro Glaciano Nogueira, Neto Jorge Vaz, Baiocchi Otávio Cesar Carvalho Guimaraes, Abdo André Neder Ramires, Arrais-Rodrigues Celso, Fogliatto Laura M, Bigni Ricardo de Sá, Schaffel Rony, Biasoli Irene, Pereira Juliana, Nabhan Samir Kanaan, Souza Cármino Antônio de, Chiattone Carlos Sérgio
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Américas Oncologia, São Paulo, SP, Brazil.
AC Camargo Cancer Center, São Paulo, SP, Brazil.
Hematol Transfus Cell Ther. 2020 Apr-Jun;42(2):103-110. doi: 10.1016/j.htct.2020.04.002. Epub 2020 Apr 17.
The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.
新型冠状病毒(新冠病毒-19)疫情目前被视为全球大流行,影响着全球超过130万人。癌症患者面临罹患重症的风险,包括入住重症监护病房(ICU)、需要有创通气或死亡的风险更高。在疫情期间,淋巴系统恶性肿瘤患者的管理颇具挑战,因为这类患者需要多次前往医院就诊和住院,存在免疫抑制情况,且需要进行化疗、放疗和干细胞移植。在本文中,我们将重点关注新冠疫情期间淋巴系统恶性肿瘤患者的实际管理,着重降低患者的风险。